Vaxart (VXRT) began the week with a monster Monday session. Shares of the vaccine specialist surged by 47% after the biotech announced it had been given the go ahead from the FDA to commence the Phase 1 clinical trial of its oral COVID-19 vaccine candidate.The study will evaluate the vaccine’s effect on healthy adults between the ages of 18 to 55, examining the safety and reactogenicity of a two-dose regimen.The trial’s commencement couldn’t have come sooner for this high-flying coronavirus stock, as the small cap is significantly behind peers in the development of its COVID-19 vaccine program. However, based on …read more
Source:: Yahoo Finance
